- Home
- IMCR vs ATRC Comparison
IMCR vs ATRC Comparison
Compare IMCR & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ATRC
- Stock Information
- Founded
- IMCR 2008
- ATRC 2000
- Country
- IMCR United Kingdom
- ATRC United States
- Employees
- IMCR N/A
- ATRC N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ATRC Medical/Dental Instruments
- Sector
- IMCR Health Care
- ATRC Health Care
- Exchange
- IMCR Nasdaq
- ATRC Nasdaq
- Market Cap
- IMCR 1.5B
- ATRC 1.5B
- IPO Year
- IMCR 2021
- ATRC 2005
- Fundamental
- Price
- IMCR $36.60
- ATRC $34.57
- Analyst Decision
- IMCR Buy
- ATRC Strong Buy
- Analyst Count
- IMCR 10
- ATRC 10
- Target Price
- IMCR $58.13
- ATRC $49.60
- AVG Volume (30 Days)
- IMCR 440.3K
- ATRC 581.4K
- Earning Date
- IMCR 05-07-2025
- ATRC 04-29-2025
- Dividend Yield
- IMCR N/A
- ATRC N/A
- EPS Growth
- IMCR N/A
- ATRC N/A
- EPS
- IMCR N/A
- ATRC N/A
- Revenue
- IMCR $333,581,000.00
- ATRC $480,076,000.00
- Revenue This Year
- IMCR $25.96
- ATRC $14.63
- Revenue Next Year
- IMCR $8.06
- ATRC $12.62
- P/E Ratio
- IMCR N/A
- ATRC N/A
- Revenue Growth
- IMCR 25.75
- ATRC 15.79
- 52 Week Low
- IMCR $23.15
- ATRC $18.94
- 52 Week High
- IMCR $49.05
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- IMCR 71.46
- ATRC 60.03
- Support Level
- IMCR $31.14
- ATRC $31.95
- Resistance Level
- IMCR $33.30
- ATRC $34.08
- Average True Range (ATR)
- IMCR 1.94
- ATRC 1.14
- MACD
- IMCR 0.57
- ATRC 0.31
- Stochastic Oscillator
- IMCR 96.12
- ATRC 94.66
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.